


Product Name: Recombinant Cynomolgus B7-1 (C-6His)
Catalog #: PHV1662



Summary

Name	B7-1/CD80/T-lymphocyte Activation Antigen CD80
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Cynomolgus T-lymphocyte Activation Antigen CD80 is produced by our Mammalian expression system and the target gene encoding Val35-Asn242 is expressed with a 6His tag at the C-terminus.
Accession #	G7NXN7
Host	Human Cells
Species	Cynomolgus
Predicted Molecular Mass	24.7 KDa
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Background

Product Name: Recombinant Cynomolgus B7-1 (C-6His)
Catalog #: PHV1662



Alternative Names

T-lymphocyte activation antigen CD80; Activation B7-1 antigen; B7; CD80

Background

Cynomologous Cluster of Differentiation 80, also called B7-1, is a member of cell surface immunoglobulin superfamily. It is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. CD80 plays key, yet distinct roles in the activation of T cells. B7-1/CD80 and B7-2/CD86, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T- and B- cell responses. CD80 is mostly expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Note

For Research Use Only , Not for Diagnostic Use.